Results From a Large, Multicenter, Retrospective Analysis On Radium223 Use in Metastatic Castration-resistant Prostate Cancer (mCRPC) in the Triveneto Italian Region
Articolo
Data di Pubblicazione:
2018
Abstract:
Radium 223 was introduced for metastatic castration-resistant prostate cancer based on the results of a randomized controlled trial showing risk reduction for death and skeletal events. Our aim was to evaluate the outcome of patients receiving radium 223 in a real-world setting.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
Bone metastases; Prostate cancer; Radiometabolic therapy; Radium223; Real-world setting
Elenco autori:
Maruzzo, Marco; Basso, Umberto; Borsatti, Eugenio; Evangelista, Laura; Alongi, Filippo; Caffo, Orazio; Maines, Francesca; Galuppo, Sara; De Vivo, Rocco; Zustovich, Fable; Palleschi, Dario; Zivi, Andrea; Sava, Teodoro; Sorarù, Mariella; Iacovelli, Roberto; Nicodemo, Maurizio; Baier, Susanne; Fratino, Lucia; Zagonel, Vittorina
Link alla scheda completa:
Pubblicato in: